Skip to main content
Erschienen in: Clinical Rheumatology 3/2014

01.03.2014 | Original Article

Relationship between serum leptin level and disease activity in patients with systemic sclerosis

verfasst von: Mahmut Budulgan, Banu Dilek, Şevin Buluttekin Dağ, İbrahim Batmaz, İsmail Yıldız, Mustafa Akif Sarıyıldız, Remzi Çevik, Kemal Nas

Erschienen in: Clinical Rheumatology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

To determine the relationship between serum leptin levels and disease activity in systemic sclerosis (SSc). A total of 60 subjects (30 controls and 30 patients) were included. The inflammatory markers and leptin levels were evaluated and body mass index (BMI) was measured for both groups. The assessment of the skin involvement was performed based on the modified Rodnan skin score (mRSS). Disease activity was evaluated according to the Valentini scleroderma disease activity index. There was a significant difference between the patient and control groups in terms of BMI (p < 0.05); however there was no difference with regards to age and gender (p > 0.05). Valentini scores and mRSS were determined to be significantly higher in active patients (n = 14) than in inactive patients (n = 16) (p < 0.05). No significant difference was determined between groups in terms of leptin levels (p > 0.05). However, leptin levels were significantly lower in active patients than in inactive patients (p < 0.05). We found a significant positive correlation between serum leptin and BMI (p < 0.05), and leptin and serum C3 levels (p < 0.05); no relationship was detected between leptin and other parameters. Leptin can be used as an activity marker in SSc. Further studies, including larger series, should be carried out to clarify this relationship.
Literatur
1.
Zurück zum Zitat Gilliland BC (2001) Systemic sclerosis (scleroderma). In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (eds) Harrison’s principles of internal medicine, 15th edn. McGraw-Hil, New York, pp 1937–1945 Gilliland BC (2001) Systemic sclerosis (scleroderma). In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (eds) Harrison’s principles of internal medicine, 15th edn. McGraw-Hil, New York, pp 1937–1945
2.
Zurück zum Zitat Valentini G, Della Rossa A, Bombardieri S (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indices. Ann Rheum 60:592–598CrossRef Valentini G, Della Rossa A, Bombardieri S (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indices. Ann Rheum 60:592–598CrossRef
3.
Zurück zum Zitat Clements P, Lachenbruch P, Seibold J, Wigley FM (1995) Inter- and intraobserver variability of total skin thickness score (modified Rodnan) in systemic sclerosis (SSc). J Rheum 22:1281–1285PubMed Clements P, Lachenbruch P, Seibold J, Wigley FM (1995) Inter- and intraobserver variability of total skin thickness score (modified Rodnan) in systemic sclerosis (SSc). J Rheum 22:1281–1285PubMed
4.
Zurück zum Zitat Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheum 26:2159–2167PubMed Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheum 26:2159–2167PubMed
5.
Zurück zum Zitat Mantzoros CS, Flier JS (2000) Editorial: leptin as a therapeutic agent—trials and tribulations. J Clin Endocrinol Metab 85(11):4000–4002PubMed Mantzoros CS, Flier JS (2000) Editorial: leptin as a therapeutic agent—trials and tribulations. J Clin Endocrinol Metab 85(11):4000–4002PubMed
6.
Zurück zum Zitat Aslan K, Serdar Z, Tokullugil AH (2004) Multifonksiyonel hormon: leptin. Uludag Üniversitesi tıp fakültesi Dergisi 30:113–118 Aslan K, Serdar Z, Tokullugil AH (2004) Multifonksiyonel hormon: leptin. Uludag Üniversitesi tıp fakültesi Dergisi 30:113–118
7.
Zurück zum Zitat Prions KB, O’Rahilly S (1997) Regulation of adipose cell number in man. Clin Sci 92:311 Prions KB, O’Rahilly S (1997) Regulation of adipose cell number in man. Clin Sci 92:311
8.
Zurück zum Zitat Satoh N, Ogawa Y, Katsuura G et al (1997) Pathophysiological significance of the obese gene product, leptin, in ventromedial hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety effect in VMH-lesioned rats. Endocrinology 138(3):947–954PubMed Satoh N, Ogawa Y, Katsuura G et al (1997) Pathophysiological significance of the obese gene product, leptin, in ventromedial hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety effect in VMH-lesioned rats. Endocrinology 138(3):947–954PubMed
9.
Zurück zum Zitat Clement K (1999) Leptin and the genetics of obesity. Acta Pediatr Suppl 88:51–57CrossRef Clement K (1999) Leptin and the genetics of obesity. Acta Pediatr Suppl 88:51–57CrossRef
10.
Zurück zum Zitat Fantuzzi G, Faggioni R (2000) Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 68:437–446PubMed Fantuzzi G, Faggioni R (2000) Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 68:437–446PubMed
11.
Zurück zum Zitat Anders HJ, Rihl M, Heufelder A, Loch O, Schattenkirchner M (1999) Leptin serum levels are not correlated with disease activity in patients with rheumatoid arthritis. Metabolism 48(6):745–748PubMedCrossRef Anders HJ, Rihl M, Heufelder A, Loch O, Schattenkirchner M (1999) Leptin serum levels are not correlated with disease activity in patients with rheumatoid arthritis. Metabolism 48(6):745–748PubMedCrossRef
12.
Zurück zum Zitat Popa C, Netea MG, Radstake TR, Van der Meer JW, Stalenhoef AF, van Riel PL et al (2005) Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 64(8):1195–1198PubMedCentralPubMedCrossRef Popa C, Netea MG, Radstake TR, Van der Meer JW, Stalenhoef AF, van Riel PL et al (2005) Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 64(8):1195–1198PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Gunaydin R, Kaya T, Atay A, Olmez N, Hur A, Koseoglu M (2006) Serum leptin levelsvin rheumatoid arthritis and relationship with disease activity. South Med J 99(10):1078–1083PubMedCrossRef Gunaydin R, Kaya T, Atay A, Olmez N, Hur A, Koseoglu M (2006) Serum leptin levelsvin rheumatoid arthritis and relationship with disease activity. South Med J 99(10):1078–1083PubMedCrossRef
14.
Zurück zum Zitat Bokarewa M, Bokarew D, Hultgren O, Tarkowski A (2003) Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis 62(10):952–956PubMedCentralPubMedCrossRef Bokarewa M, Bokarew D, Hultgren O, Tarkowski A (2003) Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis 62(10):952–956PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Toussirot E, Streit G, Nguyen NU, Dumoulin G, Le Huédé G, Saas P et al (2007) Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 56(10):1383–1389PubMedCrossRef Toussirot E, Streit G, Nguyen NU, Dumoulin G, Le Huédé G, Saas P et al (2007) Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 56(10):1383–1389PubMedCrossRef
16.
Zurück zum Zitat Sari I, Demir T, Kozaci LD, Akar S, Kavak T, Birlik M et al (2007) Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. Clin Rheumatol 26(9):1427–1432PubMedCrossRef Sari I, Demir T, Kozaci LD, Akar S, Kavak T, Birlik M et al (2007) Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. Clin Rheumatol 26(9):1427–1432PubMedCrossRef
17.
Zurück zum Zitat Park MC, Lee SW, Choi ST, Park YB, Lee SK (2007) Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 36(2):101–106PubMedCrossRef Park MC, Lee SW, Choi ST, Park YB, Lee SK (2007) Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 36(2):101–106PubMedCrossRef
18.
Zurück zum Zitat Kavuncu S, Koç F, Kurt M, Eryüksel B, Ortaç S, Ozdal P, Firat E (2005) Evaluation of serum leptin concentration in Behçet’s disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol 243(11):1158–1160PubMedCrossRef Kavuncu S, Koç F, Kurt M, Eryüksel B, Ortaç S, Ozdal P, Firat E (2005) Evaluation of serum leptin concentration in Behçet’s disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol 243(11):1158–1160PubMedCrossRef
19.
Zurück zum Zitat Evereklioglu C, Inalöz HS, Kirtak N, Doganay S, Bülbül M, Ozerol E, Er H, Ozbek E (2002) Serum leptin concentration is increased in patients with Behçet’s syndrome and is correlated with disease activity. Br J Dermatol 147(2):331–336PubMedCrossRef Evereklioglu C, Inalöz HS, Kirtak N, Doganay S, Bülbül M, Ozerol E, Er H, Ozbek E (2002) Serum leptin concentration is increased in patients with Behçet’s syndrome and is correlated with disease activity. Br J Dermatol 147(2):331–336PubMedCrossRef
20.
Zurück zum Zitat Wisłowska M, Rok M, Stepień K, Kuklo-Kowalska A (2008) Serum leptin in systemic lupus erythematosus. Rheumatol Int 28(5):467–473PubMedCrossRef Wisłowska M, Rok M, Stepień K, Kuklo-Kowalska A (2008) Serum leptin in systemic lupus erythematosus. Rheumatol Int 28(5):467–473PubMedCrossRef
21.
Zurück zum Zitat Kotulska A, Kucharz EJ, Brzezińska-Wcisło L, Wadas U (2001) A decreased serum leptin level in patients with systemic sclerosis. Clin Rheumatol 20(4):300–302PubMedCrossRef Kotulska A, Kucharz EJ, Brzezińska-Wcisło L, Wadas U (2001) A decreased serum leptin level in patients with systemic sclerosis. Clin Rheumatol 20(4):300–302PubMedCrossRef
22.
Zurück zum Zitat Riccieri V, Stefanantoni K, Vasile M, Macrì V, Sciarra I, Iannace N, Alessandri C, Valesini G (2011) Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol 29(2 Suppl 65):S46–S52PubMed Riccieri V, Stefanantoni K, Vasile M, Macrì V, Sciarra I, Iannace N, Alessandri C, Valesini G (2011) Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol 29(2 Suppl 65):S46–S52PubMed
23.
Zurück zum Zitat Pehlivan Y, Onat AM, Ceylan N, Turkbeyler IH, Buyukhatipoglu H, Comez G, Babacan T, Tarakcioglu M (2012) Serum leptin, resistin and TNF-α levels in patients with systemic sclerosis: the role of adipokines in scleroderma. Int J Rheum Dis 15(4):374–379PubMedCrossRef Pehlivan Y, Onat AM, Ceylan N, Turkbeyler IH, Buyukhatipoglu H, Comez G, Babacan T, Tarakcioglu M (2012) Serum leptin, resistin and TNF-α levels in patients with systemic sclerosis: the role of adipokines in scleroderma. Int J Rheum Dis 15(4):374–379PubMedCrossRef
24.
Zurück zum Zitat Masi AT, Rodnan GP, Medsger TA Jr et al (1980) Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef Masi AT, Rodnan GP, Medsger TA Jr et al (1980) Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef
25.
Zurück zum Zitat Clements P, Lachenbruch P, Siebold J et al (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22(7):1281–1285PubMed Clements P, Lachenbruch P, Siebold J et al (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22(7):1281–1285PubMed
26.
Zurück zum Zitat Valentini G, D’Angelo S, Della Rossa A, Bencivelli W, Bombardieri S (2003) European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 62(9):904–905PubMedCentralPubMedCrossRef Valentini G, D’Angelo S, Della Rossa A, Bencivelli W, Bombardieri S (2003) European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 62(9):904–905PubMedCentralPubMedCrossRef
27.
28.
Zurück zum Zitat La Cava A, Alviggi C, Matarese G (2004) Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 82:4–11PubMedCrossRef La Cava A, Alviggi C, Matarese G (2004) Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 82:4–11PubMedCrossRef
29.
Zurück zum Zitat Shamsuzzaman AS, Winnicki M, Wolk R et al (2004) Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 109:2181–2185PubMedCrossRef Shamsuzzaman AS, Winnicki M, Wolk R et al (2004) Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 109:2181–2185PubMedCrossRef
30.
Zurück zum Zitat Dagogo JS, Fanelli C, Paramore D et al (1996) Plasma leptin and insulin relationships in obese and nonobese humans (abstract). Diabetes 45:695–698CrossRef Dagogo JS, Fanelli C, Paramore D et al (1996) Plasma leptin and insulin relationships in obese and nonobese humans (abstract). Diabetes 45:695–698CrossRef
Metadaten
Titel
Relationship between serum leptin level and disease activity in patients with systemic sclerosis
verfasst von
Mahmut Budulgan
Banu Dilek
Şevin Buluttekin Dağ
İbrahim Batmaz
İsmail Yıldız
Mustafa Akif Sarıyıldız
Remzi Çevik
Kemal Nas
Publikationsdatum
01.03.2014
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 3/2014
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-013-2459-0

Weitere Artikel der Ausgabe 3/2014

Clinical Rheumatology 3/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.